Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29867943 | 1.00 | CASP3 (0.32) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL17485426 | 0.92 | NPC1 (0.35) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL20712022 | 0.89 | CASP3 (0.32) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL26024103 | 0.88 | HTT (0.35) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL22636487 | 0.87 | CASP3 (0.33) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL31172125 | 0.87 | CASP3 (0.33) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL20711945 | 0.87 | MEN1 (0.35) | NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL28931092 | 0.86 | GBA1 (0.35) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL25020373 | 0.85 | CASP3 (0.32) | CASP3SENP8SENP7SENP6NPC1 | |
| SCHEMBL29773056 | 0.85 | CASP3 (0.32) | CASP3SENP8SENP7SENP6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565582-A1 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM MONOSULFATE | Icrom SpA (IT) | 2025-06-11 | — | — | EP | claimed |
| WO-2024028711-A1 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM MONOSULFATE | ICROM S.P.A. (IT) | 2024-02-08 | — | — | WO | claimed |
| EP-4565582-A1 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM MONOSULFATE | Icrom SpA (IT) | 2025-06-11 | — | — | EP | disclosed |
| US-20250145610-A1 | CRYSTALLINE FORM OF ISAVUCONAZONIUM SULFATE AND A PROCESS FOR ITS PREPARATION | ALIVUS LIFE SCIENCES LIMITED (IN) | 2025-05-08 | — | — | US | disclosed |
| US-20250092053-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| US-12247033-B2 | Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| WO-2025008993-A1 | Improved process for the preparation of Glycine, N-methyl-, [2-[[[1-[1-((2R,3R)-3-[4-(4-cyanophenyl)-2-thiazolyl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4H-1,2,4-triazolium-4-yl]ethoxy]carbonyl]methylamino]-3-pyridinyl]methyl ester, sulfate (1:1) | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-01-09 | — | — | WO | disclosed |
| CN-119192067-A | Preparation method of isaconazole side chain intermediate C1 | 山东齐都药业有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4472978-A1 | CRYSTALLINE FORM OF ISAVUCONAZONIUM SULFATE AND A PROCESS FOR ITS PREPARATION | Glenmark Life Sciences Limited (IN) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024189550-A1 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM SULFATE AND ITS CRYSTALLINE FORMS | APITORIA PHARMA PRIVATE LIMITED (IN) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024189550-A1 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM SULFATE AND ITS CRYSTALLINE FORMS | APITORIA PHARMA PRIVATE LIMITED (IN) | 2024-09-19 | — | — | WO | disclosed |
| WO-2020227337-A1 | PRODRUG COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2016016766-A2 | A PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM OR ITS SALT THEREOF | WOCKHARDT LIMITED (IN) | 2016-02-04 | — | — | WO | disclosed |
| US-7459561-B2 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2008-12-02 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-7189858-B2 | N-phenyl substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA AG (CH) | 2007-03-13 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2007-02-01 | — | — | US | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247033-B2 | Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors | CGAS, SSB, STING1 | CASP3 1850/4885SENP8 4057/4885SENP7 3939/4885 |
| US-20250145610-A1 | CRYSTALLINE FORM OF ISAVUCONAZONIUM SULFATE AND A PROCESS FOR ITS PREPARATION | STS, MPST, SI | CASP3 2584/4885SENP8 1191/4885SENP7 811/4885 |
| US-20070027322-A1 | N-substituted carbamoyloxyalkyl-azolium derivatives | ERG28, CYP51A1, NAALAD2 | CASP3 69/4885SENP8 1858/4885SENP7 2234/4885 |
| US-20250092053-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | CGAS, SSB, STING1 | CASP3 1850/4885SENP8 4057/4885SENP7 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.